CD63是前列腺癌的诊断标志物,也是根治性前列腺切除术后生化进展的预后标志物。

IF 2 4区 生物学 Q3 CELL BIOLOGY
Elisabeth Dingendorf, Marit Bernhardt, Isabella Federica Bollen, Tobias Kreft, Anna Katrin Scherping, Xiaolin Zhou, Manuel Ritter, Jörg Ellinger, Carsten Stephan, Glen Kristiansen
{"title":"CD63是前列腺癌的诊断标志物,也是根治性前列腺切除术后生化进展的预后标志物。","authors":"Elisabeth Dingendorf, Marit Bernhardt, Isabella Federica Bollen, Tobias Kreft, Anna Katrin Scherping, Xiaolin Zhou, Manuel Ritter, Jörg Ellinger, Carsten Stephan, Glen Kristiansen","doi":"10.14670/HH-18-981","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.</p><p><strong>Methods: </strong>CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence. In addition, CD63 expression in 251 of the 281 patients with prostate cancer was compared with CD63 expression in matched benign tissue samples (490 tissue samples). The analysis was performed automatically using the open-source software QuPath<sup>©</sup> and tested for statistical significance. For comparison with the diagnostic markers AMACR and GOLPH2, CD63 was analyzed in an additional cohort of 198 Prostate cancers.</p><p><strong>Results: </strong>CD63 expression was found in 100% of prostate cancer cases and benign tissue spots. Increased CD63 expression was significantly associated with higher tumor stage (pT), tumor grade (ISUP), as well as shorter progression-free survival (PFS). Compared with the CD63 intensity of benign tissue, expression in tumor tissue was higher in >80% of cases. In addition, combining the expression of CD63 and AMACR, positivity reached 97.2%, making CD63 a promising diagnostic biomarker in challenging cases.</p><p><strong>Conclusions: </strong>CD63 is commonly overexpressed in prostate cancer, and higher levels are associated with earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in primary prostate cancer.</p>","PeriodicalId":13164,"journal":{"name":"Histology and histopathology","volume":" ","pages":"18981"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.\",\"authors\":\"Elisabeth Dingendorf, Marit Bernhardt, Isabella Federica Bollen, Tobias Kreft, Anna Katrin Scherping, Xiaolin Zhou, Manuel Ritter, Jörg Ellinger, Carsten Stephan, Glen Kristiansen\",\"doi\":\"10.14670/HH-18-981\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.</p><p><strong>Methods: </strong>CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence. In addition, CD63 expression in 251 of the 281 patients with prostate cancer was compared with CD63 expression in matched benign tissue samples (490 tissue samples). The analysis was performed automatically using the open-source software QuPath<sup>©</sup> and tested for statistical significance. For comparison with the diagnostic markers AMACR and GOLPH2, CD63 was analyzed in an additional cohort of 198 Prostate cancers.</p><p><strong>Results: </strong>CD63 expression was found in 100% of prostate cancer cases and benign tissue spots. Increased CD63 expression was significantly associated with higher tumor stage (pT), tumor grade (ISUP), as well as shorter progression-free survival (PFS). Compared with the CD63 intensity of benign tissue, expression in tumor tissue was higher in >80% of cases. In addition, combining the expression of CD63 and AMACR, positivity reached 97.2%, making CD63 a promising diagnostic biomarker in challenging cases.</p><p><strong>Conclusions: </strong>CD63 is commonly overexpressed in prostate cancer, and higher levels are associated with earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in primary prostate cancer.</p>\",\"PeriodicalId\":13164,\"journal\":{\"name\":\"Histology and histopathology\",\"volume\":\" \",\"pages\":\"18981\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Histology and histopathology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.14670/HH-18-981\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histology and histopathology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14670/HH-18-981","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们旨在分析CD63,这是一种细胞表面蛋白,与几种癌症的肿瘤侵袭性相关,包括乳腺癌、结直肠癌和肺癌,以及前列腺癌中的黑色素瘤。方法:对281例原发性前列腺癌患者的CD63表达进行免疫组化分析。结果与临床病理参数相关,包括生化复发。此外,将281例前列腺癌患者中251例的CD63表达与匹配的良性组织样本(490例组织样本)中的CD63表达进行比较。使用开源软件QuPath©自动进行分析,并进行统计显著性检验。为了与诊断标记AMACR和GOLPH2进行比较,CD63在另一个198例前列腺癌队列中进行了分析。结果:CD63在100%的前列腺癌病例及良性组织斑点中均有表达。CD63表达升高与较高的肿瘤分期(pT)、肿瘤分级(ISUP)以及较短的无进展生存期(PFS)显著相关。与良性组织相比,肿瘤组织中CD63的表达水平在bb80 %的病例中较高。此外,结合CD63和AMACR的表达,阳性表达率达到97.2%,使CD63成为具有挑战性病例的有希望的诊断生物标志物。结论:CD63在前列腺癌中普遍过表达,且CD63水平升高与早期肿瘤生化进展相关;因此,CD63是原发性前列腺癌的一种很有前景的诊断和预后生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.

Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.

Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence. In addition, CD63 expression in 251 of the 281 patients with prostate cancer was compared with CD63 expression in matched benign tissue samples (490 tissue samples). The analysis was performed automatically using the open-source software QuPath© and tested for statistical significance. For comparison with the diagnostic markers AMACR and GOLPH2, CD63 was analyzed in an additional cohort of 198 Prostate cancers.

Results: CD63 expression was found in 100% of prostate cancer cases and benign tissue spots. Increased CD63 expression was significantly associated with higher tumor stage (pT), tumor grade (ISUP), as well as shorter progression-free survival (PFS). Compared with the CD63 intensity of benign tissue, expression in tumor tissue was higher in >80% of cases. In addition, combining the expression of CD63 and AMACR, positivity reached 97.2%, making CD63 a promising diagnostic biomarker in challenging cases.

Conclusions: CD63 is commonly overexpressed in prostate cancer, and higher levels are associated with earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in primary prostate cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Histology and histopathology
Histology and histopathology 生物-病理学
CiteScore
3.90
自引率
0.00%
发文量
232
审稿时长
2 months
期刊介绍: HISTOLOGY AND HISTOPATHOLOGY is a peer-reviewed international journal, the purpose of which is to publish original and review articles in all fields of the microscopical morphology, cell biology and tissue engineering; high quality is the overall consideration. Its format is the standard international size of 21 x 27.7 cm. One volume is published every year (more than 1,300 pages, approximately 90 original works and 40 reviews). Each volume consists of 12 numbers published monthly online. The printed version of the journal includes 4 books every year; each of them compiles 3 numbers previously published online.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信